Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that concentrates on delivering innovative therapies through its lipid nanocrystal (LNC) platform delivery technology. The LNC platform enables the encapsulation of small molecules and oligonucleotides, allowing targeted extrahepatic delivery to desired cells and tissues while minimizing systemic toxicity. The company’s lead product candidate, MAT2203, is an oral formulation of amphotericin B that leverages the LNC platform to provide a potentially safer and more convenient alternative to intravenous amphotericin B for the treatment of serious invasive fungal infections. Beyond MAT2203, Matinas had been advancing an internal pipeline that uses the LNC platform for small‑molecule oncology applications and for the formulation and delivery of small oligonucleotides with a focus on anti‑inflammatory therapeutics. Following an 80% reduction in workforce in October 2024, the company paused further clinical development of MAT2203 and halted internal work on its early‑stage pipeline while it explores strategic alternatives, including a potential sale, licensing, or partnership for MAT2203. Matinas continues to maintain the MAT2203 Investigational New Drug Application, prosecute related intellectual property, and support patients in its expanded/compassionate use access program with the assistance of external medical consultants.
Matinas BioPharma does not currently generate revenue from product sales because MAT2203 remains in clinical development and the company has no approved commercial products. Its primary source of cash has been through equity financings, including the sale of common stock and warrants in transactions such as the April 2024 offering that generated approximately $10 million in gross proceeds and the February 2025 purchase of Series C convertible preferred stock that yielded $3.3 million in gross proceeds before expenses. The company also seeks to monetize its assets through potential licensing, partnership, or sale transactions for MAT2203, which would provide future revenue upon successful negotiation. In addition, Matinas incurs modest research and development expenses, reporting $85 thousand for the year ended December 31, 2025, reflecting the reduced scale of operations after the workforce reduction.
The antifungal market in which Matinas competes is substantial and growing, with the global antifungal market valued at approximately $15.8 billion in 2023 and projected to reach about $20.5 billion by 2030, while the global invasive fungal infection market exceeded $7.2 billion in 2021 and is expected to grow to $10.4 billion by 2030. MAT2203, if approved, would compete against established intravenous and oral antifungal agents such as AmBisome (liposomal amphotericin B), caspofungin, micafungin, fluconazole, voriconazole, posaconazole, isavuconazole, and the newer investigational drugs olorofim and fosmanogepix. Matinas believes its LNC platform offers a competitive advantage by enabling oral delivery of amphotericin B with a reduced risk of nephrotoxicity, potentially allowing longer treatment durations and outpatient use, which addresses an unmet need for safer, more convenient therapies in patients with limited options due to toxicity or resistance. The company has also secured regulatory incentives for MAT2203, including Qualified Infectious Disease Product, Fast Track, and Orphan Drug designations, which may provide additional exclusivity and development benefits if the product gains approval.
The company’s intended patient population comprises individuals with life‑threatening invasive fungal infections who have few or no effective treatment alternatives, notably immunocompromised patients such as organ transplant recipients, those undergoing chemotherapy for hematologic malignancies, and individuals on prolonged immunosuppressive therapy for autoimmune conditions. Through its expanded/compassionate use access program, Matinas has made MAT2203 available to a limited number of patients at several major medical institutions, including the University of Michigan, Johns Hopkins Hospital, Nationwide Children’s Hospital, City of Hope, Vanderbilt University Medical Center, the National Institutes of Health, Children’s Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and the University of California, San Diego School of Medicine. As of the latest disclosure, 37 patients have been enrolled in the program, with a subset treated for infections such as aspergillosis, candidiasis, mucormycosis, and other fungal pathogens, and the majority of participants have been post‑transplant or undergoing treatment for underlying malignancies. The program has demonstrated that patients who experienced renal toxicity from prior amphotericin B therapy saw renal function return to baseline after switching to MAT2203, with no further renal adverse events reported during extended treatment.